Overview
Aurora Cannabis fiscal Q1 2026 rev rises 17%, driven by medical cannabis growth
Adjusted EBITDA for fiscal Q1 grows 209%, reflecting strong operational performance
Co maintains strong balance sheet with $186 mln cash and debt-free cannabis business
Outlook
Aurora expects Q2 2026 net revenue to grow year-over-year
Company anticipates 8%-12% growth in Global Medical Cannabis segment
Aurora sees adjusted gross margins rising by 250-475 basis points
Company expects significant cash outflows to impact Q2 2026 free cash flow
Result Drivers
MEDICAL CANNABIS - 37% increase in global medical cannabis revenue driven by higher sales in Australia, Germany, Poland, and the UK
INTERNATIONAL GROWTH - 85% growth in international medical cannabis revenue, now accounting for 57% of global medical cannabis net revenue
PLANT PROPAGATION - 4% revenue increase due to organic growth and expanded product offerings, despite inventory write-offs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue |
| C$64.80 mln |
|
Q1 Adjusted EBITDA |
| C$10.80 mln |
|
Q1 Adjusted Gross Margin |
| 52.0% |
|
Q1 Adjusted Gross Profit |
| C$49 mln |
|
Q1 Net Income from Cont Ops |
| -C$19.40 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 19 three months ago
Press Release: ID:nCNWvWTKZa